CARLSBAD, Calif. & AUSTIN, Texas--(BUSINESS WIRE)--Invitrogen Corporation (NASDAQ: IVGN), a provider of essential life science technologies for research, production and diagnostics, and Luminex Corporation (NASDAQ: LMNX), today announced the renewal and expansion of Invitrogen’s license and supply agreement for Luminex’s multiplexed analyte detection technology and systems. The new agreement extends the lifetime of the license and provides Invitrogen with access to Luminex’s next-generation multiplex detection platforms.
